We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting currently retinal degenerative eye diseases with have significant unmet medical needs, such as Stargardt disease (STGD1) or Geographic Atrophy (GA) in advanced dry age-related macular degeneration (dry AMD), in addition to specific metabolic diseases.
We believe our lead product candidate, Tinlarebant, or LBS-008 if approved, would provide a novel treatment option where there currently is none. Tinlarebant is novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of these toxins. In clinical trials, Tinlarebant has demonstrated its target specificity and potency that we believe could be clinically meaningful to treat STGD1 patients.
We are currently conducting a two-year Phase 2 study and have initiated the two-year Phase 3 study (DRAGON) of Tinlarebant in adolescent STGD1 subjects. DRAGON study is a multi-center, randomized, double masked, placebo controlled study to evaluate the safety and efficacy of Tinlarebant in the treatment of adolescent STGD1 patients. We plan to begin enrolling patients in a two-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy (GA) in mid-2023. PHOENIX will be a multicenter, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in GA subjects.
Data Provided by Refinitiv. Minimum 15 minutes delayed.